Despite having made rapid progress in this field of HIV vaccination research in the past few years, a treatment for the deadly HIV-AIDS is still the dream of many. Human immunodeficiency virus [HIV]being the sole cause for this disease, is a rapidly mutating virus which targets the T lymphocyte cells and thereby brings down the hosts immune system. There are specific antibodies synthesized in vivo that are transiently effective against the virus but, as the disease progresses the helper cells are destroyed by the virus with which the antibody secretion also halts. Several studies are carried out that aims at curing the disease. Recombinant vaccines are the focus at present where viral vectors with HIV antigens are used to trigger the immune response in the host and provide immunity from HIV. The vaccine research is making some strong progress recently mainly due to the success of the RV144 trial. The various clinical trials that were carried out lackedefficacy like AIDSVAX trials, Step trials, and Phambili, while a few were stopped midway like HVTN 505. HVTN100 trial which is currently being carried out in South Africa is the next phase of the famous RV-144 trial and is expected to procure better results than RV144. With a lot of money being spent on the best brains of the decade, a cure for HIV is a certain in the future. © 2016, International Journal of Pharmacy and Technology. All rights reserved.